Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.


Journal

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
ISSN: 1524-4733
Titre abrégé: Value Health
Pays: United States
ID NLM: 100883818

Informations de publication

Date de publication:
02 2020
Historique:
received: 03 01 2020
accepted: 05 01 2020
entrez: 2 3 2020
pubmed: 3 3 2020
medline: 23 6 2020
Statut: ppublish

Résumé

Healthcare resource allocation decisions made under conditions of uncertainty may turn out to be suboptimal. In a resource constrained system in which there is a fixed budget, these suboptimal decisions will result in health loss. Consequently, there may be value in reducing uncertainty, through the collection of new evidence, to make better resource allocation decisions. This value can be quantified using a value of information (VOI) analysis. This report, from the ISPOR VOI Task Force, introduces VOI analysis, defines key concepts and terminology, and outlines the role of VOI for supporting decision making, including the steps involved in undertaking and interpreting VOI analyses. The report is specifically aimed at those tasked with making decisions about the adoption of healthcare or the funding of healthcare research. The report provides a number of recommendations for good practice when planning, undertaking, or reviewing the results of VOI analyses.

Identifiants

pubmed: 32113617
pii: S1098-3015(20)30027-9
doi: 10.1016/j.jval.2020.01.001
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

139-150

Subventions

Organisme : Medical Research Council
ID : G0601721
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/J000434/1
Pays : United Kingdom
Organisme : Department of Health
ID : PDF-2012-05-258
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : R01 HL126804
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Auteurs

Elisabeth Fenwick (E)

Pharmerit International, Oxford, England, UK. Electronic address: efenwick@pharmerit.com.

Lotte Steuten (L)

Office of Health Economics, London, England, UK.

Saskia Knies (S)

National Health Care Institute (Zorginstituut Nederland), Diemen, The Netherlands.

Salah Ghabri (S)

French National Authority for Health, Paris, France.

Anirban Basu (A)

The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle, WA, USA.

James F Murray (JF)

Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, USA.

Hendrik Erik Koffijberg (HE)

Department of Health Technology & Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands.

Mark Strong (M)

School of Health and Related Research, University of Sheffield, Sheffield, England, UK.

Gillian D Sanders Schmidler (GD)

Duke-Margolis Center for Health Policy, Duke Clinical Research Institute and Department of Population Health Sciences, Duke University, Durham, NC, USA.

Claire Rothery (C)

Centre for Health Economics, University of York, York, England, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH